PINK:GTHP

Guided Therapeutics Stock Insider Trading

Healthcare > Medical - Devices

Buy GTHP

*Your capital is at risk

$0.228

+0 (+0%)

At Close: Jun 03, 2026

Guided Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 83.10. In total, the insiders bought 27.53M and sold 552.63M GTHP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	83.10
● Buy	27.53M shares
● Sell	552.63M shares
74% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 03, 2025 Buy	Stock Options A-Award	James Michael C Director	Director	110 000 Value: $15.4K
Jun 03, 2025 Buy	Stock Options A-Award	James Michael C Director	Director	110 000 Value: $15.4K
Jun 03, 2025 Buy	Stock Options A-Award	Grujic Alan Director	Director	110 000 Value: $15.4K
Jun 03, 2025 Buy	Stock Options A-Award	Imhoff John E Director	Director	110 000 Value: $15.4K
Jun 03, 2025 Buy	Stock Options A-Award	Imhoff John E Director	Director	110 000 Value: $15.4K
Jun 03, 2025 Buy	Stock Options A-Award	Grujic Alan Director	Director	110 000 Value: $15.4K
Apr 10, 2025 Buy	Common Stock J-Other	Blumberg Richard P.	Director	55 853 Value: $6K
Apr 10, 2025 Buy	Common Stock J-Other	Blumberg Richard P.	Director	165 481 Value: $16.5K
Apr 10, 2025 Buy	Common Stock J-Other	Blumberg Richard P.	Director	165 481 Value: $16.5K
Apr 10, 2025 Buy	Common Stock J-Other	Blumberg Richard P.	Director	55 853 Value: $6K
Apr 10, 2025 Buy	Common Stock J-Other	Imhoff John E	Director	6 365 Value: $637
Mar 18, 2025 Buy	Common Stock P-Purchase	Imhoff John E	Director	263 069 Value: $26.3K
Mar 18, 2025 Buy	Common Stock P-Purchase	Imhoff John E	Director	1 000 000 Value: $100.0K
Mar 18, 2025 Buy	Warrants P-Purchase	Imhoff John E	Director	263 069 Value: $34.2K
Mar 18, 2025 Buy	Warrants P-Purchase	Imhoff John E	Director	1 000 000 Value: $130.0K
Mar 18, 2025 Buy	Common Stock P-Purchase	Imhoff John E	Director	263 069 Value: $26.3K
Mar 13, 2025 Buy	Preferred Series E Stock P-Purchase	Imhoff John E	Director	150 Value: $4.50M
Mar 13, 2025 Buy	Preferred Series E Stock P-Purchase	Imhoff John E	Director	150 Value: $4.50M
Mar 11, 2025 Buy	Common Stock J-Other	Imhoff John E	Director	2 258 690 Value: $286.0K
Mar 11, 2025 Sell	Preferred Series C Stock J-Other	Imhoff John E	Director	286 Value: $32.3M
Mar 07, 2025 Buy	Preferred Series C Stock P-Purchase	Imhoff John E	Director	286 Value: $32.3M
Mar 06, 2025 Buy	Common Stock J-Other	Imhoff John E	Director	4 801 500 Value: $2.40M
Mar 06, 2025 Buy	Common Stock J-Other	Imhoff John E	Director	900 000 Value: $86.4K
Mar 06, 2025 Sell	Preferred Series C2 Stock J-Other	Imhoff John E	Director	2 401 Value: $1K
Mar 06, 2025 Sell	Preferred Series D Stock J-Other	Imhoff John E	Director	300 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GUIDED THERAPEUTICS, INC.

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its n...

Read Full Profile Here